Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. Only Nucala 100mg SC is licenced for use.¹
Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within the first 3 injections¹
The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder.¹
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie ;. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
PM-IE-MPL-WCNT-200017 | March 2021